In a study evaluating the effectiveness and safety of Alexion’s Soliris® (eculizumab) in preventing thrombotic microangiopathy (TMA) — the formation of blood clots in small blood vessels throughout the body — in patients with atypical hemolytic uremic syndrome (aHUS), researchers reported a 74 percent lower TMA event rate with ongoing Soliris treatment with labeled dosing compared with discontinuation of Soliris therapy.